Computational Modeling of Tumor Response to Drug Release from Vasculature-Bound Nanoparticles

Systemically injected nanoparticle (NPs) targeting tumor vasculature offer a venue for anti-angiogenic therapies as well as cancer detection and imaging. Clinical application has been limited, however, due to the challenge of elucidating the complex interplay of nanotechnology, drug, and tumor parameters. A critical factor representing the likelihood of endothelial adhesion is the NP vascular affinity, a function of vascular receptor expression and NP size and surface-bound ligand density. We propose a theoretical framework to simulate the tumor response to vasculature-bound drug-loaded NPs and examine the interplay between NP distribution and accumulation as a function of NP vascular affinity, size, and drug loading and release characteristics. The results show that uniform spatial distribution coupled with high vascular affinity is achievable for smaller NPs but not for larger sizes. Consequently, small (100 nm) NPs with high vascular affinity are predicted to be more effective than larger (1000 nm) NPs with similar affinity, even though small NPs have lower drug loading and local drug release compared to the larger NPs. Medium vascular affinity coupled with medium or larger sized NPs is also effective due to a more uniform distribution with higher drug loading and release. Low vascular affinity hampered treatment efficacy regardless of NP size, with larger NPs additionally impeded by heterogeneous distribution and drug release. The results further show that increased drug diffusivity mainly benefits heterogeneously distributed NPs, and would negatively affect efficacy otherwise due to increased wash-out. This model system enables evaluation of efficacy for vascular-targeted drug-loaded NPs as a function of critical NP, drug, and tumor parameters.

[1]  Kostas Kostarelos,et al.  Physiologically based pharmacokinetic modeling of nanoparticles. , 2010, ACS nano.

[2]  Mauro Ferrari,et al.  Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. , 2012, AIP advances.

[3]  Mauro Ferrari,et al.  Intravascular Delivery of Particulate Systems: Does Geometry Really Matter? , 2008, Pharmaceutical Research.

[4]  P. Cullis,et al.  Drug Delivery Systems: Entering the Mainstream , 2004, Science.

[5]  Mauro Ferrari,et al.  Modeling of nanotherapeutics delivery based on tumor perfusion , 2013, New journal of physics.

[6]  Min Wu,et al.  The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems. , 2013, Journal of theoretical biology.

[7]  Sei-Young Lee,et al.  Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows , 2009, Nanotechnology.

[8]  Mark A. J. Chaplain,et al.  The effect of interstitial pressure on therapeutic agent transport: coupling with the tumor blood and lymphatic vascular systems. , 2014, Journal of theoretical biology.

[9]  Milan Makale,et al.  Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis , 2008, Proceedings of the National Academy of Sciences.

[10]  V. Muzykantov,et al.  Reduction of nanoparticle avidity enhances the selectivity of vascular targeting and PET detection of pulmonary inflammation. , 2013, ACS nano.

[11]  Raoul Kopelman,et al.  Vascular Targeted Nanoparticles for Imaging and Treatment of Brain Tumors , 2006, Clinical Cancer Research.

[12]  M Ferrari,et al.  The adhesive strength of non-spherical particles mediated by specific interactions. , 2006, Biomaterials.

[13]  Daniel A Hammer,et al.  Effect of microvillus deformability on leukocyte adhesion explored using adhesive dynamics simulations. , 2005, Biophysical journal.

[14]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[15]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[16]  M. Ferrari Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[17]  M Ferrari,et al.  Size and shape effects in the biodistribution of intravascularly injected particles. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[18]  Orhan Nalcioglu,et al.  Nanotechnology in Cancer Drug Therapy: A Biocomputational Approach , 2006 .

[19]  S. McDougall,et al.  Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies. , 2006, Journal of theoretical biology.

[20]  J. Reineke,et al.  Mathematical modelling of nanoparticle biodistribution: extrapolation among intravenous, oral and pulmonary administration routes , 2011 .

[21]  R K Jain,et al.  Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. , 1990, Cancer research.

[22]  D. Papahadjopoulos,et al.  Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.

[23]  W. Arap,et al.  Display technologies: Application for the discovery of drug and gene delivery agents , 2006, Advanced Drug Delivery Reviews.

[24]  B. Schrefler,et al.  Optimizing particle size for targeting diseased microvasculature: from experiments to artificial neural networks , 2011, International journal of nanomedicine.

[25]  S. McDougall,et al.  Multiscale modelling and nonlinear simulation of vascular tumour growth , 2009, Journal of mathematical biology.

[26]  R. Jain,et al.  Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.

[27]  S. Slack,et al.  Particle diameter influences adhesion under flow. , 2001, Biophysical journal.

[28]  Steve Wereley,et al.  BioMEMS and Biomedical Nanotechnology , 2006 .

[29]  Daniel A Hammer,et al.  Quantifying nanoparticle adhesion mediated by specific molecular interactions. , 2008, Langmuir : the ACS journal of surfaces and colloids.

[30]  R K Jain,et al.  Extravascular diffusion in normal and neoplastic tissues. , 1984, Cancer research.

[31]  Mingguang Li,et al.  Delineating intracellular pharmacokinetics of paclitaxel delivered by PLGA nanoparticles , 2013, Drug Delivery and Translational Research.

[32]  H. Daniel Ou-Yang,et al.  The influence of size, shape and vessel geometry on nanoparticle distribution , 2013, Microfluidics and nanofluidics.

[33]  Bin Chen,et al.  Predictive Models of Diffusive Nanoparticle Transport in 3-Dimensional Tumor Cell Spheroids , 2013, The AAPS Journal.

[34]  John H Phan,et al.  Computational nanomedicine: modeling of nanoparticle-mediated hyperthermal cancer therapy. , 2013, Nanomedicine.

[35]  R. Auerbach Vascular endothelial cell differentiation: organ-specificity and selective affinities as the basis for developing anti-cancer strategies. , 1991, International journal of radiation biology.

[36]  V. Torchilin Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[37]  K. Avgoustakis,et al.  Physiologically based pharmacokinetic modeling of PLGA nanoparticles with varied mPEG content , 2012, International journal of nanomedicine.

[38]  Vittorio Cristini,et al.  A Computational Model for Predicting Nanoparticle Accumulation in Tumor Vasculature , 2013, PloS one.

[39]  Mauro Ferrari,et al.  An integrated approach for the rational design of nanovectors for biomedical imaging and therapy. , 2010, Advances in genetics.

[40]  J. Folkman Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[41]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .